Corrosion Inhibitors From China; Scheduling of the Final Phase of Countervailing Duty and Anti-Dumping Duty Investigations, 63139-63141 [2020-22027]
Download as PDF
Federal Register / Vol. 85, No. 194 / Tuesday, October 6, 2020 / Notices
Issued: October 1, 2020.
Lisa Barton,
Secretary to the Commission.
INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–638 and 731–
TA–1473 (Final)]
[FR Doc. 2020–22026 Filed 10–5–20; 8:45 am]
BILLING CODE 7020–02–P
Corrosion Inhibitors From China;
Scheduling of the Final Phase of
Countervailing Duty and Anti-Dumping
Duty Investigations
INTERNATIONAL TRADE
COMMISSION
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
[Investigation Nos. 701–TA–458 and 731–
TA–1154 (Second Review)]
Kitchen Appliance Shelving and Racks
From China
Determinations
On the basis of the record 1 developed
in the subject five-year reviews, the
United States International Trade
Commission (‘‘Commission’’)
determines, pursuant to the Tariff Act of
1930 (‘‘the Act’’), that revocation of the
antidumping and countervailing duty
orders on kitchen appliance shelving
and racks from China would be likely to
lead to continuation or recurrence of
material injury to an industry in the
United States within a reasonably
foreseeable time.
Background
The Commission instituted these
reviews on February 3, 2020 (85 FR
5980) and determined on May 8, 2020
that it would conduct expedited reviews
(85 FR 55321, September 4, 2020).
The Commission made these
determinations pursuant to section
751(c) of the Act (19 U.S.C. 1675(c)). It
completed and filed its determinations
in these reviews on September 30, 2020.
The views of the Commission are
contained in USITC Publication 5123
(September 2020), entitled Kitchen
Appliance Shelving and Racks from
China: Investigation Nos. 701–TA–458
and 731–TA–1154 (Second Review).
By order of the Commission.
Issued: September 30, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020–22006 Filed 10–5–20; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
BILLING CODE 7020–02–P
1 The record is defined in § 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR 207.2(f)).
VerDate Sep<11>2014
17:52 Oct 05, 2020
Jkt 253001
The Commission hereby gives
notice of the scheduling of the final
phase of antidumping and
countervailing duty investigation Nos.
701–TA–638 and 731–TA–1473 (Final)
pursuant to the Tariff Act of 1930 (‘‘the
Act’’) to determine whether an industry
in the United States is materially
injured or threatened with material
injury, or the establishment of an
industry in the United States is
materially retarded, by reason of
imports of corrosion inhibitors from
China, provided for in subheading
2933.99.82 of the Harmonized Tariff
Schedule of the United States,
preliminarily determined by the
Department of Commerce (‘‘Commerce’’)
to be subsidized and sold at less-thanfair-value.
DATES: September 10, 2020.
FOR FURTHER INFORMATION CONTACT:
Lawrence Jones ((202) 205–3358), Office
of Investigations, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these investigations may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION:
Scope.—For purposes of these
investigations, Commerce has defined
the subject merchandise as covered by
these investigations is tolyltriazole and
benzotriazole. This includes
tolyltriazole and benzotriazole of all
grades and forms, including their
sodium salt forms. Tolyltriazole is
technically known as Tolyltriazole
IUPAC 4,5 methylbenzotriazole. It can
also be identified as 4,5 methyl
benzotriazole, tolutriazole, TTA, and
TTZ.
SUMMARY:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
63139
Benzotriazole is technically known as
IUPAC 1,2,3-Benzotriazole. It can also
be identified as 1,2,3 Benzotriazole, 1,2Aminozophenylene, 1H-Benzotriazole,
and BTA.
All forms of tolyltriazole and
benzotriazole, including but not limited
to flakes, granules, pellets, prills,
needles, powder, or liquids, are
included within the scope of these
petitions.
The scope includes tolyltriazole/
sodium tolyltriazole and benzotriazole/
sodium benzotriazole that are combined
or mixed with other products. For such
combined products, only the
tolyltriazole/sodium tolyltriazole and
benzotriazole/sodium benzotriazole
component is covered by the scope of
these investigations. Tolyltriazole and
sodium tolyltriazole that have been
combined with other products is
included within the scope, regardless of
whether the combining occurs in third
countries.
Tolyltriazole, sodium tolyltriazole,
benzotriazole and sodium benzotriazole
that is otherwise subject to these
investigations is not excluded when
commingled with tolyltriazole, sodium
tolyltriazole, benzotriazole, or sodium
benzotriazole from sources not subject
to these investigations. Only the subject
merchandise component of such
commingled products is covered by the
scope of these investigations.
A combination or mixture is excluded
from this investigation if the total
tolyltriazole or benzotriazole component
of the combination or mixture
(regardless of the source or sources)
comprises less than 5 percent of the
combination or mixture, on a dry weight
basis.
Notwithstanding the foregoing
language, a tolyltriazole or benzotriazole
combination or mixture that is
transformed through a chemical reaction
into another product, such that, for
example, the tolyltriazole or
benzotriazole can no longer be separated
from the other products through a
distillation or other process is excluded
from this investigation.
Tolyltriazole has the Chemical
Abstracts Service (‘‘CAS’’) registry
number 29385–43–1. Tolyltriazole is
classified under Harmonized Tariff
Schedule of the United States
(‘‘HTSUS’’) statistical reporting number
2933.99.82.20.
Sodium Tolyltriazole has the CAS
registry number 64665–57–2 and is
classified under HTSUS statistical
reporting number 2933.99.82.90.
Benzotriazole has the CAS registry
number #95–14–7 and is classified
under HTSUS statistical reporting
number 2933.99.82.10.
E:\FR\FM\06OCN1.SGM
06OCN1
khammond on DSKJM1Z7X2PROD with NOTICES
63140
Federal Register / Vol. 85, No. 194 / Tuesday, October 6, 2020 / Notices
Sodium Benzotriazole has the CAS
registry number 15217–42–2. Sodium
Benzotriazole is classified under HTSUS
statistical reporting number
2933.99.82.90.
Although the HTSUS subheadings
and CAS registry numbers are provided
for convenience and customs purposes,
the written description of the scope of
these investigations is dispositive.
Background.—The final phase of
these investigations is being scheduled
pursuant to sections 705(b) and 731(b)
of the Tariff Act of 1930 (19 U.S.C.
1671d(b) and 1673d(b)), as a result of
affirmative preliminary determinations
by Commerce that certain benefits
which constitute subsidies within the
meaning of § 703 of the Act (19 U.S.C.
1671b) are being provided to
manufacturers, producers, or exporters
in China of corrosion inhibitors, and
that such products are being sold in the
United States at less than fair value
within the meaning of § 733 of the Act
(19 U.S.C. 1673b). The investigations
were requested in petitions filed on
February 5, 2020, by Wincom
Incorporated, Blue Ash, Ohio.
For further information concerning
the conduct of this phase of the
investigations, hearing procedures, and
rules of general application, consult the
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A and C (19 CFR part 207).
Participation in the investigations and
public service list.—Persons, including
industrial users of the subject
merchandise and, if the merchandise is
sold at the retail level, representative
consumer organizations, wishing to
participate in the final phase of these
investigations as parties must file an
entry of appearance with the Secretary
to the Commission, as provided in
§ 201.11 of the Commission’s rules, no
later than 21 days prior to the hearing
date specified in this notice. A party
that filed a notice of appearance during
the preliminary phase of the
investigations need not file an
additional notice of appearance during
this final phase. The Secretary will
maintain a public service list containing
the names and addresses of all persons,
or their representatives, who are parties
to the investigations.
Please note the Secretary’s Office will
accept only electronic filings during this
time. Filings must be made through the
Commission’s Electronic Document
Information System (EDIS, https://
edis.usitc.gov.) No in-person paperbased filings or paper copies of any
electronic filings will be accepted until
further notice.
VerDate Sep<11>2014
17:52 Oct 05, 2020
Jkt 253001
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.—Pursuant to
§ 207.7(a) of the Commission’s rules, the
Secretary will make BPI gathered in the
final phase of these investigations
available to authorized applicants under
the APO issued in the investigations,
provided that the application is made
no later than 21 days prior to the
hearing date specified in this notice.
Authorized applicants must represent
interested parties, as defined by 19
U.S.C. 1677(9), who are parties to the
investigations. A party granted access to
BPI in the preliminary phase of the
investigations need not reapply for such
access. A separate service list will be
maintained by the Secretary for those
parties authorized to receive BPI under
the APO.
Staff report.—The prehearing staff
report in the final phase of these
investigations will be placed in the
nonpublic record on January 6, 2021,
and a public version will be issued
thereafter, pursuant to § 207.22 of the
Commission’s rules.
Hearing.— The Commission will hold
a hearing in connection with the final
phase of these investigations beginning
at 9:30 a.m. on Thursday, January 21,
2021. Information about the place and
form of the hearing, including about
how to participate in and/or view the
hearing, will be posted on the
Commission’s website at https://
www.usitc.gov/calendarpad/
calendar.html. Interested parties should
check the Commission’s website
periodically for updates. Requests to
appear at the hearing should be filed in
writing with the Secretary to the
Commission on or before Thursday,
January 14, 2021. A nonparty who has
testimony that may aid the
Commission’s deliberations may request
permission to present a short statement
at the hearing. All parties and
nonparties desiring to appear at the
hearing and make oral presentations
should attend a prehearing conference
to be held at 9:30 a.m. on Friday,
January 15, 2021. Oral testimony and
written materials to be submitted at the
public hearing are governed by sections
201.6(b)(2), 201.13(f), and 207.24 of the
Commission’s rules. Parties must submit
any request to present a portion of their
hearing testimony in camera no later
than 7 business days prior to the date of
the hearing.
Written submissions.—Each party
who is an interested party shall submit
a prehearing brief to the Commission.
Prehearing briefs must conform with the
provisions of § 207.23 of the
Commission’s rules; the deadline for
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
filing is January 13, 2021. Parties may
also file written testimony in connection
with their presentation at the hearing, as
provided in § 207.24 of the
Commission’s rules, and posthearing
briefs, which must conform with the
provisions of § 207.25 of the
Commission’s rules. The deadline for
filing posthearing briefs is January 28,
2021. In addition, any person who has
not entered an appearance as a party to
the investigations may submit a written
statement of information pertinent to
the subject of the investigations,
including statements of support or
opposition to the petition, on or before
January 28, 2021. On February 17, 2021,
the Commission will make available to
parties all information on which they
have not had an opportunity to
comment. Parties may submit final
comments on this information on or
before February 19, 2021, but such final
comments must not contain new factual
information and must otherwise comply
with § 207.30 of the Commission’s rules.
All written submissions must conform
with the provisions of § 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of §§ 201.6, 207.3, and
207.7 of the Commission’s rules. The
Commission’s Handbook on Filing
Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
Additional written submissions to the
Commission, including requests
pursuant to § 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with §§ 201.16(c) and
207.3 of the Commission’s rules, each
document filed by a party to the
investigations must be served on all
other parties to the investigations (as
identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Authority: These investigations are
being conducted under authority of title
VII of the Tariff Act of 1930; this notice
is published pursuant to § 207.21 of the
Commission’s rules.
By order of the Commission.
E:\FR\FM\06OCN1.SGM
06OCN1
63141
Federal Register / Vol. 85, No. 194 / Tuesday, October 6, 2020 / Notices
Issued: October 1, 2020.
Lisa Barton,
Secretary to the Commission.
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 3, 2020,
Halo Pharmaceutical Inc, 30 North
Jefferson Road, Whippany, New Jersey
07981, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
[FR Doc. 2020–22027 Filed 10–5–20; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Controlled
substances
Drug Enforcement Administration
Drug
codes
Schedule
[Docket No. DEA–727]
Dihydromorphine ......
Hydromorphone ........
Bulk Manufacturer of Controlled
Substances Application: Halo
Pharmaceutical, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Halo Pharmaceutical, Inc. has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 7, 2020. Such
persons may also file a written request
for a hearing on the application on or
before December 7, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
9145
9150
I
II
The company plans to manufacture
Hydromorphone (9150) for distribution
to its customers. Dihydromorphine
(9145) is an intermediate in the
manufacture of Hydromorphone and is
not for commercial distribution. No
other activity for these drug codes is
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–22076 Filed 10–5–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–726]
ACTION:
Notice of application.
S&B Pharma, LLC has applied
to be registered as a bulk manufacturer
of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 7, 2020. Such
persons may also file a written request
for a hearing on the application on or
before December 7, 2020.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on August 25, 2020, S&B
Pharma, LLC, 405 South Motor Avenue,
Azusa, California 91702, applied to be
registered as an bulk manufacturer of
the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
Bulk Manufacturer of Controlled
Substances Application: S&B Pharma,
LLC
Drug Enforcement
Administration, Justice.
AGENCY:
Controlled substance
Drug code
khammond on DSKJM1Z7X2PROD with NOTICES
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Amphetamine ...................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Tapentadol .......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for use in product development and for
commercial sales to its customers. In
reference to drug code 7360 (Marihuana)
and 7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture
both as synthetic substances. No other
activity for these drug codes is
authorized for this registration.
William T. McDermott,
Assistant Administrator.
2010
7360
7370
1100
1105
1205
1724
2270
8333
9780
9801
Drug Enforcement Administration
[Docket No. DEA–725]
[FR Doc. 2020–22075 Filed 10–5–20; 8:45 am]
Importer of Controlled Substances
Application: Wildlife Laboratories, LLC
BILLING CODE 4410–09–P
Drug Enforcement
Administration, Justice.
ACTION:
17:52 Oct 05, 2020
Jkt 253001
I
I
I
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
AGENCY:
VerDate Sep<11>2014
Schedule
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
E:\FR\FM\06OCN1.SGM
Notice of application.
06OCN1
Agencies
[Federal Register Volume 85, Number 194 (Tuesday, October 6, 2020)]
[Notices]
[Pages 63139-63141]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-22027]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation Nos. 701-TA-638 and 731-TA-1473 (Final)]
Corrosion Inhibitors From China; Scheduling of the Final Phase of
Countervailing Duty and Anti-Dumping Duty Investigations
AGENCY: United States International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Commission hereby gives notice of the scheduling of the
final phase of antidumping and countervailing duty investigation Nos.
701-TA-638 and 731-TA-1473 (Final) pursuant to the Tariff Act of 1930
(``the Act'') to determine whether an industry in the United States is
materially injured or threatened with material injury, or the
establishment of an industry in the United States is materially
retarded, by reason of imports of corrosion inhibitors from China,
provided for in subheading 2933.99.82 of the Harmonized Tariff Schedule
of the United States, preliminarily determined by the Department of
Commerce (``Commerce'') to be subsidized and sold at less-than-fair-
value.
DATES: September 10, 2020.
FOR FURTHER INFORMATION CONTACT: Lawrence Jones ((202) 205-3358),
Office of Investigations, U.S. International Trade Commission, 500 E
Street SW, Washington, DC 20436. Hearing-impaired persons can obtain
information on this matter by contacting the Commission's TDD terminal
on 202-205-1810. Persons with mobility impairments who will need
special assistance in gaining access to the Commission should contact
the Office of the Secretary at 202-205-2000. General information
concerning the Commission may also be obtained by accessing its
internet server (https://www.usitc.gov). The public record for these
investigations may be viewed on the Commission's electronic docket
(EDIS) at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION:
Scope.--For purposes of these investigations, Commerce has defined
the subject merchandise as covered by these investigations is
tolyltriazole and benzotriazole. This includes tolyltriazole and
benzotriazole of all grades and forms, including their sodium salt
forms. Tolyltriazole is technically known as Tolyltriazole IUPAC 4,5
methylbenzotriazole. It can also be identified as 4,5 methyl
benzotriazole, tolutriazole, TTA, and TTZ.
Benzotriazole is technically known as IUPAC 1,2,3-Benzotriazole. It
can also be identified as 1,2,3 Benzotriazole, 1,2-Aminozophenylene,
1H-Benzotriazole, and BTA.
All forms of tolyltriazole and benzotriazole, including but not
limited to flakes, granules, pellets, prills, needles, powder, or
liquids, are included within the scope of these petitions.
The scope includes tolyltriazole/sodium tolyltriazole and
benzotriazole/sodium benzotriazole that are combined or mixed with
other products. For such combined products, only the tolyltriazole/
sodium tolyltriazole and benzotriazole/sodium benzotriazole component
is covered by the scope of these investigations. Tolyltriazole and
sodium tolyltriazole that have been combined with other products is
included within the scope, regardless of whether the combining occurs
in third countries.
Tolyltriazole, sodium tolyltriazole, benzotriazole and sodium
benzotriazole that is otherwise subject to these investigations is not
excluded when commingled with tolyltriazole, sodium tolyltriazole,
benzotriazole, or sodium benzotriazole from sources not subject to
these investigations. Only the subject merchandise component of such
commingled products is covered by the scope of these investigations.
A combination or mixture is excluded from this investigation if the
total tolyltriazole or benzotriazole component of the combination or
mixture (regardless of the source or sources) comprises less than 5
percent of the combination or mixture, on a dry weight basis.
Notwithstanding the foregoing language, a tolyltriazole or
benzotriazole combination or mixture that is transformed through a
chemical reaction into another product, such that, for example, the
tolyltriazole or benzotriazole can no longer be separated from the
other products through a distillation or other process is excluded from
this investigation.
Tolyltriazole has the Chemical Abstracts Service (``CAS'') registry
number 29385-43-1. Tolyltriazole is classified under Harmonized Tariff
Schedule of the United States (``HTSUS'') statistical reporting number
2933.99.82.20.
Sodium Tolyltriazole has the CAS registry number 64665-57-2 and is
classified under HTSUS statistical reporting number 2933.99.82.90.
Benzotriazole has the CAS registry number #95-14-7 and is classified
under HTSUS statistical reporting number 2933.99.82.10.
[[Page 63140]]
Sodium Benzotriazole has the CAS registry number 15217-42-2. Sodium
Benzotriazole is classified under HTSUS statistical reporting number
2933.99.82.90.
Although the HTSUS subheadings and CAS registry numbers are
provided for convenience and customs purposes, the written description
of the scope of these investigations is dispositive.
Background.--The final phase of these investigations is being
scheduled pursuant to sections 705(b) and 731(b) of the Tariff Act of
1930 (19 U.S.C. 1671d(b) and 1673d(b)), as a result of affirmative
preliminary determinations by Commerce that certain benefits which
constitute subsidies within the meaning of Sec. 703 of the Act (19
U.S.C. 1671b) are being provided to manufacturers, producers, or
exporters in China of corrosion inhibitors, and that such products are
being sold in the United States at less than fair value within the
meaning of Sec. 733 of the Act (19 U.S.C. 1673b). The investigations
were requested in petitions filed on February 5, 2020, by Wincom
Incorporated, Blue Ash, Ohio.
For further information concerning the conduct of this phase of the
investigations, hearing procedures, and rules of general application,
consult the Commission's Rules of Practice and Procedure, part 201,
subparts A and B (19 CFR part 201), and part 207, subparts A and C (19
CFR part 207).
Participation in the investigations and public service list.--
Persons, including industrial users of the subject merchandise and, if
the merchandise is sold at the retail level, representative consumer
organizations, wishing to participate in the final phase of these
investigations as parties must file an entry of appearance with the
Secretary to the Commission, as provided in Sec. 201.11 of the
Commission's rules, no later than 21 days prior to the hearing date
specified in this notice. A party that filed a notice of appearance
during the preliminary phase of the investigations need not file an
additional notice of appearance during this final phase. The Secretary
will maintain a public service list containing the names and addresses
of all persons, or their representatives, who are parties to the
investigations.
Please note the Secretary's Office will accept only electronic
filings during this time. Filings must be made through the Commission's
Electronic Document Information System (EDIS, https://edis.usitc.gov.)
No in-person paper-based filings or paper copies of any electronic
filings will be accepted until further notice.
Limited disclosure of business proprietary information (BPI) under
an administrative protective order (APO) and BPI service list.--
Pursuant to Sec. 207.7(a) of the Commission's rules, the Secretary
will make BPI gathered in the final phase of these investigations
available to authorized applicants under the APO issued in the
investigations, provided that the application is made no later than 21
days prior to the hearing date specified in this notice. Authorized
applicants must represent interested parties, as defined by 19 U.S.C.
1677(9), who are parties to the investigations. A party granted access
to BPI in the preliminary phase of the investigations need not reapply
for such access. A separate service list will be maintained by the
Secretary for those parties authorized to receive BPI under the APO.
Staff report.--The prehearing staff report in the final phase of
these investigations will be placed in the nonpublic record on January
6, 2021, and a public version will be issued thereafter, pursuant to
Sec. 207.22 of the Commission's rules.
Hearing.-- The Commission will hold a hearing in connection with
the final phase of these investigations beginning at 9:30 a.m. on
Thursday, January 21, 2021. Information about the place and form of the
hearing, including about how to participate in and/or view the hearing,
will be posted on the Commission's website at https://www.usitc.gov/calendarpad/calendar.html. Interested parties should check the
Commission's website periodically for updates. Requests to appear at
the hearing should be filed in writing with the Secretary to the
Commission on or before Thursday, January 14, 2021. A nonparty who has
testimony that may aid the Commission's deliberations may request
permission to present a short statement at the hearing. All parties and
nonparties desiring to appear at the hearing and make oral
presentations should attend a prehearing conference to be held at 9:30
a.m. on Friday, January 15, 2021. Oral testimony and written materials
to be submitted at the public hearing are governed by sections
201.6(b)(2), 201.13(f), and 207.24 of the Commission's rules. Parties
must submit any request to present a portion of their hearing testimony
in camera no later than 7 business days prior to the date of the
hearing.
Written submissions.--Each party who is an interested party shall
submit a prehearing brief to the Commission. Prehearing briefs must
conform with the provisions of Sec. 207.23 of the Commission's rules;
the deadline for filing is January 13, 2021. Parties may also file
written testimony in connection with their presentation at the hearing,
as provided in Sec. 207.24 of the Commission's rules, and posthearing
briefs, which must conform with the provisions of Sec. 207.25 of the
Commission's rules. The deadline for filing posthearing briefs is
January 28, 2021. In addition, any person who has not entered an
appearance as a party to the investigations may submit a written
statement of information pertinent to the subject of the
investigations, including statements of support or opposition to the
petition, on or before January 28, 2021. On February 17, 2021, the
Commission will make available to parties all information on which they
have not had an opportunity to comment. Parties may submit final
comments on this information on or before February 19, 2021, but such
final comments must not contain new factual information and must
otherwise comply with Sec. 207.30 of the Commission's rules. All
written submissions must conform with the provisions of Sec. 201.8 of
the Commission's rules; any submissions that contain BPI must also
conform with the requirements of Sec. Sec. 201.6, 207.3, and 207.7 of
the Commission's rules. The Commission's Handbook on Filing Procedures,
available on the Commission's website at https://www.usitc.gov/documents/handbook_on_filing_procedures.pdf, elaborates upon the
Commission's procedures with respect to filings.
Additional written submissions to the Commission, including
requests pursuant to Sec. 201.12 of the Commission's rules, shall not
be accepted unless good cause is shown for accepting such submissions,
or unless the submission is pursuant to a specific request by a
Commissioner or Commission staff.
In accordance with Sec. Sec. 201.16(c) and 207.3 of the
Commission's rules, each document filed by a party to the
investigations must be served on all other parties to the
investigations (as identified by either the public or BPI service
list), and a certificate of service must be timely filed. The Secretary
will not accept a document for filing without a certificate of service.
Authority: These investigations are being conducted under authority
of title VII of the Tariff Act of 1930; this notice is published
pursuant to Sec. 207.21 of the Commission's rules.
By order of the Commission.
[[Page 63141]]
Issued: October 1, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020-22027 Filed 10-5-20; 8:45 am]
BILLING CODE 7020-02-P